TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Cancer Prevention: NSABP Publishes P-1 Data, Finds Risk Of Breast Cancer Cut By 49 Percent September 18, 1998
